We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

5 hedge funds and large institutions have $254K invested in Moleculin Biotech in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.08% less ownership

Funds ownership: 0.44% → 0.36% (-0.08%)

17% less funds holding

Funds holding: 6 → 5 (-1)

22% less capital invested

Capital invested by funds: $326K → $254K (-$72K)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$72.1K
2
AIM
Acrospire Investment Management
Illinois
+$14.4K
3
UBS Group
UBS Group
Switzerland
+$14.4K

Top Sellers

Rank Fund Capital Flow
1
SIM
Spark Investment Management
New York
-$124K
2
Morgan Stanley
Morgan Stanley
New York
-$14.4K
3
TRCT
Tower Research Capital (TRC)
New York
-$14.4K
4
Barclays
Barclays
United Kingdom
-$9K

MBRX Hedge Fund Activity: Q3 2016 in Review

5 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2016, worth a combined $254K — down 22% from $326K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MBRX and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $72.1K. The largest seller was Spark Investment Management, exiting entirely with an estimated $124K sold.

  • 5 institutional investors held Moleculin Biotech (MBRX) as of Q3 2016, down from 6 in Q2 2016.
  • Funds reported $254K of Moleculin Biotech stock for Q3 2016, down 22% quarter-over-quarter.
  • 3 funds opened new Moleculin Biotech positions in Q3 2016 and 4 closed out, a net change of -1 holder.
  • The largest Moleculin Biotech buyer in Q3 2016 was Virtu KCG Holdings, an estimated $72.1K added.
  • The largest Moleculin Biotech seller in Q3 2016 was Spark Investment Management, an estimated $124K sold.

Based on aggregated 13F filings for Q3 2016.